ionHP Biodecontamination Technology for Aseptic Systems - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ionHP Biodecontamination Technology for Aseptic Systems



The ionHP biodecontamination system by Telstar is used in aseptic enclosures to resolve difficulties associated with hydrogen peroxide biodecontamination processes. The ionHP technology increases the efficacy of the decontamination process and reduces degradation of construction materials by requiring a low concentration of hydrogen peroxide. In addition, the reduced bio-decontamination cycle times are possible since the process efficiency is not affected by temperature and humidity; there is no need to pre-condition the chamber prior to the hydrogen peroxide injection, according to the company.

ionHP can be used in open air and, once ionized, acts like a gas as opposed to a vapor, which offers operational, commercial, and environmental benefits. According to the company, this gives the ionHP a shorter decontamination process time and it does not require special atmospheric conditions, which eliminates the need for the air conditioning units required with traditional systems, reducing equipment cost. The ionHP also uses a base concentration of 7.5% volume, while traditional hydrogen peroxide systems use 30-35%.

This new system is also is more effective due to the positively charged droplets being attracted to the negatively charged surface areas and the ionHP does not leave behind any residue, reducing costs by shortening cleaning activities, the company reports.

Source: Telstar

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here